ALK Actualización en terapias dirigidas en CPNM ALK+

32 / 48

Intracranial PFS in Patients With Any Brain Metastases at Baseline
Treatment
Median Intracranial PFS (95%
CI)
1-Year PFS Probability, % (95%
CI)
Brigatinib (n=43) NR (11.0–NR) 67 (47–80)
Crizotinib (n=47) 5.6 months (4.1–9.2) 21 (6–42)
September 25, 2018, at . DOI: 10.1056/NEJMoa1810171